Potential mechanisms of resistance to venetoclax and strategies to circumvent it
BMC Cancer, 2017 Background Venetoclax (ABT-199), a first-in-class orally bioavailable BCL-2-selective inhibitor, was recently approved by the FDA for use in patients with 17p-deleted chronic lymphocytic leukemia who have received prior therapy.
Stephen K. Tahir +7 more
doaj +1 more source
Constitutive IP3 signaling underlies the sensitivity of B-cell cancers to the Bcl-2/IP3 receptor disruptor BIRD-2 [PDF]
, 2018 Anti-apoptotic Bcl-2 proteins are upregulated in different cancers, including diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL), enabling survival by inhibiting pro-apoptotic Bcl-2-family members and inositol 1,4,5 ...
Akl, Haidar +18 more
core +3 more sources
Significance of Bcl-2 and Bcl-6 immunostaining in B-Non Hodgkin's lymphoma
Hematology Reports, 2011 The determination of prognosis for B-Non- Hodgkin’s lymphoma (NHL) is known to be related to the multiple differences in tumor cell biology. Bcl-2 and Bcl-6 are two markers linked to germinal center B cells.
Hanan Mohamed Mahmoud +1 more
doaj +1 more source
Cells, 2020 The dynamic interplay between pro-death and pro-survival Bcl-2 family proteins is responsible for a cell’s fate. Due to the recognized relevance of this family in cancer progression and response to therapy, different efforts have made in recent years in ...
Simona D’Aguanno, Donatella Del Bufalo
doaj +1 more source
Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia [PDF]
, 2015 Several chemo-resistance mechanisms including the Bcl-2 protein family overexpression and constitutive activation of the PI3K/Akt/mTOR signaling have been documented in acute lymphoblastic leukemia (ALL), encouraging targeted approaches to circumvent ...
ALLEGRETTI, MATTEO +12 more
core +1 more source
The p53–Bcl-2 connection [PDF]
Cell Death & Differentiation, 2006 The tumor suppressor p53 and the proto-oncogene Bcl-2 were two of the earliest identified cancer genes. Mutant p53 proteins were first discovered in transformed murine cell lines,1,2 whereas Bcl-2 translocations were first identified in human follicular lymphoma.3,4,5 Despite this shared cancer relevance, they were initially thought to have little else
M T, Hemann, S W, Lowe
openaire +2 more sources
Bad expression influences time to androgen escape in prostate cancer [PDF]
, 2007 <b>OBJECTIVE</b>: To assess the role of selected downstream Bcl-2 family members (Bad, Bax, Bcl-2 and Bcl-xL) in the development of androgen-independent prostate cancer (AIPC), as androgen-deprivation therapy is the treatment of choice in ...
Bracarda S +9 more
core +1 more source
Killing of Sarcoma Cells by Proapoptotic Bcl-XS: Role of the BH3 Domain and Regulation by Bcl-XL
Neoplasia: An International Journal for Oncology Research, 2001 Kaposi's sarcoma (KS) is the most common tumor affecting AIDS patients with over 20% of these patients afflicted by this disease. Previous studies have demonstrated that KS tumor cells predominantly express the prosurvival protein Bcl-XL compared with ...
Raj. S. Mitra +6 more
doaj +1 more source
Identification of a novel BCL2-specific inhibitor that binds predominantly to the BH1 domain [PDF]
, 2016 The antiapoptotic protein BCL 2 is overexpressed in several cancers and contributes to prolonged cell survival and chemoresistance, lending itself as an excellent target for cancer therapy.
Anderson +57 more
core +1 more source
Pramanicin analog induces apoptosis in human colon cancer cells: critical roles for Bcl-2, Bim, and p38 MAPK signaling [PDF]
, 2013 Pramanicin (PMC) is an antifungal agent that was previously demonstrated to exhibit antiangiogenic and anticancer properties in a few in vitro studies. We initially screened a number of PMC analogs for their cytotoxic effects on HCT116 human colon cancer
Başağa, Hüveyda +5 more
core +1 more source